"Safe in the Wound"
NAMSA GLP Independent Laboratory Animal Study
(Full Study is Available)
“The in-life assessment for each animal was clinically normal upon entering the study and all animals remained healthy during the in-life portion of the study. There were two minor health observations (post-operative swelling & inappetence) and no adverse events noted during the study. According to the physical examinations, the clinical pathology results, the daily observations, the procedures, and the in-life assessment all animals in this study demonstrated adequate health to assess the objective of the study.”
To paraphrase the summary, other than surgical swelling at a couple of the sites and temporary loss of appetite after the surgery, all animals observed after the 4-week period were in the same condition as they were when they started. The StopsBleeding™/BleedStop™ powder in the animals' bodies had no adverse effect on any of the three animals or in any of the 12 sites.
“Mild post-operative inflammation was noted in all 3 animals, which is normal post-operative sequella. These conditions were treated with additional analgesic medications (ibuprofen & meloxicam SR) and jackets to protect the integrity of the implant sites. Mild inappetence was noted briefly in all animals, which is to be expected after a procedure. All the animals in this study were otherwise healthy throughout the in-life portion of the study.”
StopsBleeding™ and BleedStop™ are trade names of CoAg Medical LLC for their hemostatic powder and rigid foam products. Both products, StopsBleeding™ and BleedStop™, are identical except for the name. In general, BleedStop™ is marketed to consumers, and StopsBleeding™ is marketed to hospitals.